Clinical trial · no report yet · Phase 2/Phase 3
CYCLONE 2
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer
- NCT03706365 ↗
- Active not recruiting
- Eli Lilly and Company
- 27 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 18 | |
| Podcasts | 7 | |
| YouTube | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
- Phase
- Phase 2/Phase 3
- Status
- Active not recruiting
- Conditions
- Prostate Cancer
- Interventions
- Abemaciclib; Placebo; Abiraterone acetate; Prednisone
- Arms
- Abemaciclib · Experimental
- Placebo · Placebo comparator
- Enrollment
- 393
- Primary outcomes
- Radiographic Progression Free Survival (rPFS)
- Sponsor
- Eli Lilly and Company
- Start
- Nov 26, 2018
- Primary completion
- Jan 2, 2024
- Results posted
- Yes
- Registry record
- NCT03706365 · updated Aug 7, 2026
Publications
linked from the registry- Smith M, Piulats J, Todenhofer T, Lee JL, Arija JA, Mazilu L, Azad A, Alonso-Gordoa T, McGovern U, Choudhury A, Horvath L, Ye D, Han W, Suzuki H, Uemura H, McKay R, Ades S, Flechon A, Pieczonka C, Fernandes MS, Hulstijn M, Lithio A, Nacerddine K, Agarwal N; CYCLONE 2 investigators. Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2025 Nov;26(11):1489-1500. doi: 10.1016/S1470-2045(25)00475-9. PubMed 41167216